The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|February 26, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016
- Volume 11
- Issue 3
Cirrus Pharmaceuticals Announces Manufacturing for Clinical Trials
Author(s)Pharmaceutical Technology Editors
Cirrus Pharmaceuticals will launch services for manufacturing cGMP materials for early-phase clinical trials at its Raleigh-Durham, NC facility.
Advertisement
Cirrus Pharmaceuticals, a Kemwell Company, has announced that it is ready to launch services for manufacturing cGMP materials for early-phase clinical trials in a new suite at its Raleigh-Durham, NC site.
The company offers development and manufacturing capabilities for niche dosage forms. The company will manufacture metered dose inhalers (MDI) on its Pamasol pressure filling line in batch sizes up to 25L. One- and two-step filling as well as cold filling for suspension and solution MDIs will be offered.
Other services include dry powder filling in capsules for dry powder inhalers, and manufacture of nasal solutions, suspensions, and powders. Clinical manufacturing of other dosage forms that will be offered from the site are topicals, oral solids, and oral liquids.
Source: C
Articles in this issue
over 10 years ago
Small-Scale Modeling Boosts Downstream Developmentover 10 years ago
Technologies Expand Horizons of the Analytical Labover 10 years ago
Global Conflicts and CMO Impactsover 10 years ago
Hazardous Reagents for Higher Yieldsover 10 years ago
Mechanical Pipettes Have Ergonomic Designover 10 years ago
Benchtop Centrifuge Features Hybrid Rotorover 10 years ago
ICIG Acquires Sandoz Site in Germanyover 10 years ago
Recipharm Acquires Italian CDMOover 10 years ago
Patheon Signs Strategic Agreement with GrünenthalAdvertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
5